echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Good news for patients with chronic diseases!

    Good news for patients with chronic diseases!

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Sanofi China announced that two of the company's drugs in the field of cardiovascular diseases, the original clopidogrel (Polivi®) and the original irbesartan hydrochlorothiazide (Ambonol®), have been successfully included in the Guangdong Alliance's procurement list


    The inter-provincial drug procurement alliance led by Guangdong Province covers Guangdong, Shanxi, Henan, Hunan, Guangxi, Xinjiang and other provinces, and is currently one of the largest local centralized procurement alliances


    Professor Dong Yugang, director of the Department of Cardiovascular Medicine of the First Affiliated Hospital of Sun Yat-sen University, pointed out: “The centralized procurement of medicines has brought tangible benefits to the masses, and patients can afford and buy high-quality drugs


    Clopidogrel is used for the treatment of myocardial infarction, ischemic stroke, peripheral arterial disease and acute coronary syndrome (ACS); irbesartan and hydrochlorothiazide are used for the treatment of essential hypertension


    Liu Jing, general manager of Sanofi's China Innovation and Core Business Department, said: "Deeply cultivating the Chinese market for nearly 40 years, Sanofi has always adhered to the patient-centered concept and escorted the health of the Chinese people with high-quality drugs and services


    At present, cardiovascular disease has become a major type of disease that seriously threatens the health of Chinese residents, and is a major health problem that affects the country's economic and social development


    Reference: National Center for Cardiovascular Diseases.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.